Watchdogs circling DTC drug commercials

In what's becoming a daily update on the state of drug advertising, today the Los Angeles Times reviews the following:

  • Congressional investigations of ads for the newly controversial med Vytorin, made by Merck and Schering-Plough, and the non-rowing, non-practicing doctor-slash-pitchman for Pfizer's Lipitor.
  • A program that would have stepped up FDA oversight for such ads was scuttled last month for lack of funding.
  • A Consumer Reports feature called AdWatch is stepping into the breach, reviewing info included--and neglected--of national ads. Its first subject: the restless-legs syndrome med Requip.

We were just as interested, though, in which drug websites are most popular with doctors, a list published by the Chicago Tribune. Here are the top five:

  • Januvia
  • Singulair
  • Advair
  • Chantix
  • Adderal XR

The rest of the top 10, plus the 2006 list, are available at the link below. Hint: They include two of the biggest newsmakers of recent months.

- find the Manhattan Research ranking of websites
- read the report in the Los Angeles Times
- check out the website list in the Chicago Tribune

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.